. 2018 Jun 27;66(6):443–452. doi: 10.1007/s00005-018-0515-9

Table 2.

Differences in the tested parameters between the study and control groups

Parameter	PBC patients (n = 40)		Controls (n = 20)		Z	p value
Parameter	Me	Range, min–max	Me	Range, min–max	Z	p value
Lymphocytes [× 10³/ul]	1.51	0.14–13.40	2.15	1.26–3.12	− 2.723	0.006**
CD4⁺CD25⁺FOXP3⁺ Treg cells [%]	3.79	0.65–7.20	7.91	5.42–11.26	− 5.660	0.000***
CD4⁺CD25⁺FOXP3⁺ Treg cells [× 10³/ul]	0.06	0.00–0.16	0.18	0.07–0.33	− 5.123	0.000***
IL-17A⁺CD3⁺CD4⁺ Th17 lymphocytes [%]	13.53	3.54–32.75	5.16	0.34–15.65	4.550	0.000***
IL-17A⁺CD3⁺CD4⁺ Th17 lymphocytes [× 10³/ul]	0.24	0.03–1.56	0.12	0.00–0.46	2.615	0.009**
CD3⁻/CD16⁺CD56⁺ NK cells [%]	22.37	10.25–37.50	12.40	5.06–17.18	4.792	0.000***
CD3⁻/CD16⁺CD56⁺ NK cells [10³/mm³]	0.34	0.02–2.88	0.26	0.11–0.54	2.060	0.039*
CD3⁺/CD16⁺CD56⁺ NKT-like cells [%]	5.75	2.74–10.94	2.79	1.11–4.27	4.792	0.000***
CD3⁺/CD16⁺CD56⁺ NKT-like cells [10³/mm³]	0.09	0.01–0.74	0.07	0.02–0.13	1.899	0.048*
T lymphocytes CD3⁺ [%]	65.69	45.48–78.78	68.55	13.21–78.63	− 0.909	0.363^NS
T lymphocytes CD3⁺ [10³/mm³]	1.66	0.67–3.92	1.65	0.35–2.49	0.556	0.578^NS
CD3⁺CD25⁺ [%]	11.67	1.60–28.13	7.54	1.08–10.85	3.088	0.002**
CD3⁺CD25⁺ [10³/mm³]	0.28	0.04–0.91	0.16	0.03–0.38	3.190	0.001**
B lymphocytes CD19⁺ [%]	11.73	7.16–24.53	8.77	5.48–47.40	3.153	0.002**
B lymphocytes CD19⁺ [10³/mm³]	0.33	0.16–0.94	0.20	0.13–1.26	3.357	0.001***
CD4⁺CD3⁺ [%]	38.93	15.79–49.82	45.0	34.71–48.88	− 3.348	0.0008***
CD4⁺CD3⁺ [10³/mm³]	0.91	0.31–2.43	1.08	0.57–1.65	− 1.280	0.20006^NS
CD19⁺CD25⁺ [%]	3.27	0.48–13.06	1.81	0.06–5.12	2.693	0.007**
CD19⁺CD25⁺ [10³/mm³]	0.08	0.02–0.39	0.04	0.00–0.14	3.135	0.002**

NS not significant, Me median

^*p < 0.05; ^**p < 0.01; ^***p < 0.001